BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29334883)

  • 1. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
    Chikwapulo B; Ngwira B; Sagno JB; Evans R
    Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
    Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
    Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
    BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
    Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
    AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients.
    Tan Q; He YH; Yang TT; Yan DM; Wang Y; Zhao X; Liu HX; He SH; Zhou ZH
    J Microbiol Immunol Infect; 2019 Oct; 52(5):710-719. PubMed ID: 31427111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
    Lee JE; Lee S; Song SH; Kwak IS; Lee SH
    Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.
    De Waal R; Cohen K; Fox MP; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    J Int AIDS Soc; 2017 Apr; 20(1):21317. PubMed ID: 28406595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.
    Deckert A; Neuhann F; Klose C; Bruckner T; Beiersmann C; Haloka J; Nsofwa M; Banda G; Brune M; Reutter H; Rothenbacher D; Zeier M
    PLoS One; 2017; 12(9):e0184766. PubMed ID: 28931037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
    Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.
    Kaboré NF; Poda A; Zoungrana J; Da O; Ciaffi L; Semdé A; Yaméogo I; Sawadogo AB; Delaporte E; Meda N; Limou S; Cournil A
    BMC Nephrol; 2019 May; 20(1):155. PubMed ID: 31064340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana.
    Nartey ET; Tetteh RA; Yankey BA; Mantel-Teeuwisse AK; Leufkens HGM; Dodoo ANO; Lartey M
    BMC Res Notes; 2019 Jul; 12(1):445. PubMed ID: 31331365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
    De Beaudrap P; Diallo MB; Landman R; Guèye NF; Ndiaye I; Diouf A; Kane CT; Etard JF; Girard PM; Sow PS; Delaporte E;
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1221-7. PubMed ID: 20854202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
    Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
    PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.
    Boyd A; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Plaisier E; Lacombe K
    Antivir Ther; 2017; 22(1):31-42. PubMed ID: 27553871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
    Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
    Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.